<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020001100007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Artritis reumatoide y embarazo. Reporte de un caso y revisión de la bibliografía]]></article-title>
<article-title xml:lang="en"><![CDATA[Rheumatoid arthritis and pregnancy. A case report and literature review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piñel-Pérez]]></surname>
<given-names><![CDATA[Carlos Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Roso Jareño]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caliendo]]></surname>
<given-names><![CDATA[Constanza Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Steinberg-Contreras]]></surname>
<given-names><![CDATA[Gizelle Helena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Galián]]></surname>
<given-names><![CDATA[Juan José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Europea de Madrid  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Europea de Madrid  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Europea de Madrid  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>11</numero>
<fpage>806</fpage>
<lpage>814</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020001100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020001100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020001100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  La artritis reumatoide suele evolucionar durante el embarazo e, incluso, en un porcentaje importante de pacientes permanece activa. En estos casos se ha reportado elevación del riesgo de complicaciones (aborto del primer trimestre, prematuridad, preeclampsia y restricción del crecimiento intrauterino) y mayor posibilidad de cesárea.  CASO CLÍNICO:  Paciente de 40 años, primigesta, con diagnóstico previo de artritis reumatoide en remisión, que logró el embarazo después de nueve ciclos de transferencia embrionaria, permaneció en tratamiento con glucocorticoides, hidroxicloroquina y adalimumab. El embarazo transcurrió sin complicaciones obstétricas ni brotes de artritis reumatoide. Se suspendió la hidroxicloroquina y adalimumab en la semana 20. Se llevó a cabo la cesárea en la semana 39 debido al fracaso de la inducción del parto. Se obtuvo un recién nacido sano, de 3095 g, con pH de la arteria umbilical de 7.27 y Apgar 9-10. El puerperio transcurrió sin complicaciones médicas ni obstétricas.  CONCLUSIONES:  En mujeres con artritis reumatoide, la planificación del embarazo es importante porque debe iniciarse en el periodo de remisión de la enfermedad. Las complicaciones obstétricas se asocian con embarazos que se inician en la fase activa de la artritis reumatoide. El tratamiento con glucocorticoides (hidroxicloroquina y anti-TNF) en dosis bajas durante el primer trimestre del embarazo ha demostrado seguridad para la madre y el feto, y eficacia para mantener la enfermedad en remisión.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  The course of rheumatoid arthritis generally improves during pregnancy, but there are a significant number of patients who maintain active disease. In these cases, an increased risk of complications (first trimester abortions, prematurity, pre-eclampsia and restricted intrauterine growth) has been reported, as well as a higher probability of cesarean section.  CASE REPORT:  40-year-old patient, in the first pregnancy, with a previous diagnosis of rheumatoid arthritis in remission who managed to obtain her pregnancy after nine embryo transfers, maintaining treatment with glucocorticoids, hydroxychloroquine, and adalimumab. Pregnancy went without obstetric complications or outbreaks of rheumatoid arthritis. Treatment with hydroxychloroquine and adalimumab was withdrawn at week 20. Cesarean section was performed at week 39 due to failure of induction. A healthy newborn of 3095 grams was obtained, who did not require neonatal resuscitation or admission to the neonatal intensive care unit. Obtained an umbilical artery pH of 7.27 and Apgar 9/10. The puerperium passed without medical or obstetric complications.  CONCLUSION:  The planning of pregnancy is essential in women with rheumatoid arthritis, and should start in the period of remission of the disease. Obstetric complications are associated with pregnancies initiated in the active phase of rheumatoid arthritis. Treatment with low-dose glucocorticoids during the first phase of pregnancy (hydroxychloroquine, and anti-TNF biologic drugs) have shown maternal-fetal safety and efficacy in keeping the disease in remission.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[embarazo]]></kwd>
<kwd lng="es"><![CDATA[cesárea]]></kwd>
<kwd lng="es"><![CDATA[transferencia de embriones]]></kwd>
<kwd lng="es"><![CDATA[arteria umbilical]]></kwd>
<kwd lng="es"><![CDATA[adalimumab]]></kwd>
<kwd lng="es"><![CDATA[hidroxicloroquina]]></kwd>
<kwd lng="es"><![CDATA[fármacos anti-TNF]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Pregnancy]]></kwd>
<kwd lng="en"><![CDATA[Cesarean section]]></kwd>
<kwd lng="en"><![CDATA[Embryo transfer]]></kwd>
<kwd lng="en"><![CDATA[Umbilical artery]]></kwd>
<kwd lng="en"><![CDATA[Adalimumab]]></kwd>
<kwd lng="en"><![CDATA[Hydroxychloroquine]]></kwd>
<kwd lng="en"><![CDATA[Anti-TNF biological drugs]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>358</volume>
<numero>9285</numero>
<issue>9285</issue>
<page-range>903-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turrión-Nieves]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Artritis reumatoide]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2017</year>
<volume>12</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>1615-25</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crowson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2011</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>633-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10055</numero>
<issue>10055</issue>
<page-range>2023-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs; 2013 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2014</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>492-509</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smeele]]></surname>
<given-names><![CDATA[HTW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2019</year>
<volume>49</volume>
<numero>3S</numero>
<issue>3S</issue>
<page-range>S32-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fischer-Betz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schwangerschaft bei rheumatischen erkrankungen]]></article-title>
<source><![CDATA[Z Rheumatol]]></source>
<year>2020</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-73</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maynard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy in women with systemic lupus and lupus nephritis]]></article-title>
<source><![CDATA[Adv Chronic Kidney Dis]]></source>
<year>2019</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>330-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piñel-Pérez]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poliarteritis con daño pulmonar (Churg-Strauss) y embarazo Reporte de un caso y revisión bibliográfica]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2019</year>
<volume>87</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>756-61</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility in women with rheumatoid arthritis influence of disease activity and medication]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2015</year>
<volume>74</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1836-41</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norgaard]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment a nationwide cohort study. 12]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2019</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>328-34</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Förger]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jethwa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does rheumatoid arthritis really improve during pregnancy A systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2019</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>245-50</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norgaard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis and birth outcomes a Danish and Swedish nationwide prevalence study]]></article-title>
<source><![CDATA[J Intern Med]]></source>
<year>2010</year>
<volume>268</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>329-37</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Jong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility, pregnancy and lactation in rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2017</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-37</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishore]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obstetric outcomes in women with rheumatoid arthritis results from nationwide inpatient sample database 2003-2011]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2019</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>236-40</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ince-Askan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy and rheumatoid arthritis]]></article-title>
<source><![CDATA[Best Pract Res Clin Rheumatol]]></source>
<year>2015</year>
<volume>29</volume>
<numero>4-5</numero>
<issue>4-5</issue>
<page-range>580-96</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brief Report Miscarriages in female rheumatoid arthritis patients: associations with serologic findings, disease activity and antirheumatic drug treatment]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2015</year>
<volume>67</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1738-43</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermas]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2014</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>334-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birru Talabi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antirheumatic medications in pregnancy and breastfeeding]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2020</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>238-46</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alijotas-Reig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2016</year>
<volume>147</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>352-60</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IBD in pregnancy consensus group; Canadian Association of Gastroenterology The Toronto Consensus statements for the management of inflammatory bowel disease in pregnancy]]></article-title>
<source><![CDATA[Gastroenterol]]></source>
<year>2016</year>
<volume>150</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>734-57</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaudrey]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of immunomodulators and anti-TNF therapy in Pregnancy]]></article-title>
<source><![CDATA[Curr Trat Options Gastroenterol]]></source>
<year>2015</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-89</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahadevan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2013</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>286-92</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaparro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety of in utero exposure to anti-TNFalfa drugs for the treatment of infmammatory bowel disease results from the multicenter European TEDDY Study]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2018</year>
<volume>113</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>396-403</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gotestam Skorpen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EULAR points to consider for use of antirheumatic drugs before pregnancy, during pregnancy and lactation]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2016</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>795-810</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iranzo González-Cruz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Borrás]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Arranz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[García Corbalán]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jaén Revuelta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de adalimumab durante la gestación en la enfermedad de Crohn]]></article-title>
<source><![CDATA[Enferm Inflam Intest Día]]></source>
<year>2017</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>158-62</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chambers]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Birth outcomes in women who have taken adalimumab in pregnancy A prospective cohort study]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>30</label><nlm-citation citation-type="">
<collab>APILAM</collab>
<source><![CDATA[Asociación para la promoción e investigación científica y cultural de la lactancia materna]]></source>
<year>2002</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
